In the meantime...9 Oct 2017 17:54
Verona Pharma plc (Nasdaq:VRNA) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Oct. 06, 2017 (GLOBE NEWSWIRE) --
What:
Verona Pharma plc (Nasdaq:VRNA), a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases with high unmet medical need, will visit the Nasdaq MarketSite in Times Square.
In May, the Company completed financing of $90 million through a global offering comprising an IPO on the NASDAQ Global Market and a concurrent European private placement, together with a shareholder private placement. Verona Pharma was also recently awarded the 2017 Biotech and Money UK Life Science IPO of the Year Award, and named as finalist for Scrip's 2017 Financing of the Year Award.
In honor of the occasion, Jan-Anders Karlsson, Chief Executive Officer and Executive Director, along with a group of Verona Pharma colleagues, will ring the Closing Bell.
Verona Pharma's lead product candidate, RPL554, is a first-in-class inhaled compound with both bronchodilator and anti-inflammatory effects and is being investigated for the treatment of chronic obstructive pulmonary disease and cystic fibrosis, two debilitating respiratory diseases with significant gaps in current treatment options for patients.